Hepatocellular Carcinoma
If it’s your first time on this website, please read the disclaimer section.
Jun 29 – Jul 06, 2026
Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This prospective, cross-sectional diagnostic study evaluated circulating methylated SEPT9 combined with α-Fetoprotein (AFP) for hepatocellular carcinoma (HCC) detection in 574 cirrhosis patients. Methylated SEPT9 alone outperformed AFP (AUROC: 0.79 vs 0.71, P=.002). Combining them (Tier 1a) achieved 87.8% sensitivity, recovering 78% of AFP-missed HCC cases. For early-stage HCC (BCLC 0-A), Tier 1a sensitivity was 74.5% versus 23.5% for AFP, a 3.2-fold increase. This combination substantially improves HCC detection, particularly for early-stage disease amenable to curative treatment.
10.1001/jamaoncol.2026.2157
Jun 08 – Jun 15, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This consensus statement by EASL, AASLD, ILCA, and ASCO uses a modified Delphi process to develop 102 recommendations optimizing trial design and endpoints for hepatocellular carcinoma (HCC) across all disease stages, including surveillance, early, intermediate, advanced, and transplant settings. It rigorously defines target populations, stratification factors, control arms, and benchmarks for expected clinical benefit, addressing why some positive phase III trials failed regulatory or guideline adoption. Directly relevant to cancer research, the document provides a dynamic, evidence-based roadmap for accelerating therapeutic development and improving clinically meaningful outcomes in HCC. For clinicians, standardizing trial endpoints will clarify which novel therapies, particularly immunotherapies, merit adoption into practice.
10.1038/s41571-026-01160-z
May 11 – May 18, 2026
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multinational cohort study analyzed individual patient data from 4,913 patients with hepatocellular carcinoma (HCC) treated with external beam radiation therapy (EBRT) to assess overall survival (OS). Median OS was 6.8 years for BCLC-0 and 4.6 years for BCLC-A stage; in treatment-naïve patients, median OS was not reached for BCLC-0 and was 5.4 years for BCLC-A. The study directly addresses your interest in cancer-focused research, providing robust evidence that EBRT yields OS outcomes comparable to resection and thermal ablation for early-stage HCC. Clinically, these data support incorporating EBRT into BCLC decision-making algorithms for very early- and early-stage HCC patients.
10.1200/JCO-25-02399
May 04 – May 11, 2026
Hepatitis B: A Review.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This clinical review examines the epidemiology, diagnosis, and management of Hepatitis B virus (HBV), which affects 254 million people globally. Key findings highlight that chronic HBV carries an 8% to 15% five-year risk of cirrhosis, with cirrhotic patients facing a 3% to 5% annual incidence of hepatocellular carcinoma (HCC). For clinicians focused on oncology, the study demonstrates that antiviral therapies like tenofovir reduce HCC risk by approximately 50% and recommends biannual ultrasound and alpha-fetoprotein surveillance for high-risk individuals. Ultimately, the review underscores that effective HBV management and universal vaccination are primary strategies for preventing liver cancer and reducing virus-related mortality.
10.1001/jama.2026.6070
Apr 27 – May 04, 2026
International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international multisociety Delphi consensus aimed to standardize ablation margin assessment in liver tumour thermal ablation, utilizing a modified Delphi process with 72 experts. Formal consensus was reached for 150 (75%) of 199 statements, with strong agreement observed (only 6% disagreement). Experts agreed margins should be quantitatively assessed in 3D with CT/MRI, preferably intraprocedurally, and categorized as A0, A1, or A2. This provides best-practice recommendations for liver cancer treatment, standardizing practices to improve uniform outcomes for patients.
10.1016/S1470-2045(26)00143-9
International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international Delphi consensus aimed to standardize procedural and practice guidelines for thermal ablation of primary and metastatic liver tumours. Seventy-two experts achieved consensus on 94 (70%) of 135 statements across five domains, including credentialing and indications. Key findings emphasize prioritizing the percutaneous approach, ensuring margin adequacy, and recommending experienced operators (>100 cases) for complex ablations. This study directly informs clinicians treating liver cancer, providing crucial guidance to improve consistency, safety, and oncological outcomes in cancer care.
10.1016/S1470-2045(26)00114-2